07:00 , Jul 1, 2002 |  BioCentury  |  Finance

Ebb & Flow

The first regulatory setback isn't the knockout punch for Oxford GlycoSciences (LSE:OGS; OGSI), which fell 92.5p (24%) to 300p on Monday after receiving a non-approvable letter from the FDA for its Vevesca ( OGT 918...
08:00 , Mar 12, 2001 |  BioCentury  |  Emerging Company Profile

Corporate Profile

ExonHit Therapeutics S.A. , Paris, France Technology: Differential Analysis of Transcripts with Alternative Splicing (DATAS) Disease focus: NA Clinical status: NA Founded: 1997 by Bruno Tocque, Laurent Bracco and Fabien Schweighoffer Corporate partners: Aventis S.A....
07:00 , Sep 5, 2000 |  BioCentury  |  Finance

Lock-ups: No fear

A few years ago, the expiration of the 180-day lock-up on insider shares following an IPO was a surefire sign that a company's stock would go down, as venture investors got their first opportunity to...
07:00 , Sep 1, 2000 |  BC Extra  |  Financial News

ExonHit raises EUR13.9 million

ExonHit (Paris, France), which is developing its Safe-Hit predictive toxicology tool and Proof-Hit chemotherapy response diagnostic tools, raised EUR13.9 million ($12.5 million) in a private round. Investors included AGF Private Equity; BNP Private Equity; Oxford...